Treatment for hepatocellular carcinoma with tumor thrombosis in the hepatic vein or inferior vena cava:A comprehensive review  

作　　者：Zun-Yi Zhang Er-Lei Zhang Bi-Xiang Zhang Xiao-Ping Chen Wei Zhang 

机构地区：[1]Research Laboratory and Hepatic Surgery Center,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 434000,Hubei Province,China

出　　处：《World Journal of Gastrointestinal Surgery》2021年第8期796-805,共10页世界胃肠外科杂志（英文版）（电子版）

基　　金：Supported by the National Natural Science Foundation of China,No.81802767 and No.81860117.

摘　　要：Hepatocellular carcinoma(HCC)is the most common type of liver cancer with a high mortality rate worldwide.The percentage of HCC patients with vascular invasion is high.However,tumor thrombus in the hepatic vein(HVTT)has a lower incidence than tumor thrombus in the portal vein(PVTT).Conventionally,HCC patients with HVTT are treated the same as HCC patients with PVTT and offered sorafenib or other systemic agents.However,according to recent studies,it is evident that HCC with HVTT shows different outcomes when classified into different subgroups.In this review,we discuss the recent progress and changes in treatment of HCC with HVTT.

关 键 词：Hepatocellular carcinoma Vascular invasion SURGERY Transarterial chemoembolization 

分 类 号：R735.7[医药卫生—肿瘤]